Human RCTPubMed ID: 37952131·2023

Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.

New England Journal of Medicine, 2023 · n = 17604

Key finding

Semaglutide reduced cardiovascular death, heart attack, or stroke by 20% — the first anti-obesity medication to show cardiovascular benefit.

Summary

Massive cardiovascular outcomes trial demonstrating 20% reduction in major adverse cardiovascular events with semaglutide in overweight/obese adults without diabetes.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaglutideL5

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.

More research on Semaglutide

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)

New England Journal of Medicine · 2023 · Human RCT

Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)

Nature Medicine · 2022 · Human RCT

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)

JAMA · 2022 · Human RCT

STEP 3: Semaglutide for Weight Management in Severe Obesity

New England Journal of Medicine · 2022 · Human RCT

Semaglutide Effects on Heart Failure Symptoms in HFmrEF

JAMA Cardiology · 2022 · Human Pilot